Overall survival (OS) in patients after chemotherapy for cervical cancer in Poland in years 2008–2015

Wierzba, Waldemar; Jankowski, Mateusz; Płaciszewski, Krzysztof; Ciompa, Piotr; Jakimiuk, Artur; Dańska-Bidzińska, Anna

doi:10.5603/gp.a2021.0155

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poland ranks eighth in the European Union (EU) in the incidence of CC and fifth in deaths from this disease. The worldwide 5-year survival rate for CC is 48.3% versus 62.1% for EU countries [3].…”

Section: Introductionmentioning

confidence: 99%

Cervical Cancer Prevention in the Era of the COVID-19 Pandemic

Poniewierza¹,

Panek

2022

Medicina

View full text Add to dashboard Cite

Background and Objectives: Cervical cancer (CC) is the fourth most common cause of cancer-related morbidity and mortality among women worldwide. CC prevention is based on screening and HPV vaccination. The COVID-19 pandemic has caused difficulties in implementing CC-preventative measures. The aim of this study was to collect data on the implementation of CC prophylaxis in Poland provided by public and private health care with a particular focus on the impact of the COVID-19 pandemic and attempt to estimate the level of CC-screening implementation by 2026 under public and private health care. Materials and Methods: Data on the implementation of privately funded (2016–2021) and publicly funded (2014–2021) CC-preventative measures in Poland were examined. The Prophet algorithm, which positions itself as an automatic forecasting procedure and represents a local Bayesian structural time-series model, was used to predict data. The correlation test statistic was based on Pearson’s product moment correlation coefficient and follows a t distribution. An asymptotic confidence interval was given based on Fisher’s Z transform. Results: In 2021, a significantly higher population screening coverage was observed in private health care (71.91%) than in the public system (12.6%). Our estimation assumes that the adverse downward trend of population coverage (pap smear CC screening) in the public system will continue to 5.02% and in the private health system to 67.92% in 2026. Correlation analysis showed that with the increase in the sum of HPV tests and LBC, the percentage of Pap smear coverage in the private healthcare sector decreases r = −0.62, p = 0.260 df = 3, CI = [−0.97, 0.57]. The amount of HPV vaccinations provided in private health care is steadily increasing. Immunization coverage of the population of girls aged 9–18 years under private health care at the end of the observation period was 4.3% (2021). Conclusions: It is necessary to reorganize the public CC-screening system in Poland based on a uniform reporting system for tests performed in both public and private health care using the model of action proposed by us. We recommend the introduction of a national free HPV vaccination program funded by the government and implemented in public and private health care facilities.

show abstract

Section: Introductionmentioning

confidence: 99%

Cervical Cancer Prevention in the Era of the COVID-19 Pandemic

Poniewierza¹,

Panek

2022

Medicina

View full text Add to dashboard Cite

show abstract

“…The HPV vaccination coverage rate varied from ranged from 4.3% in Bulgaria to 99% in Turkmenistan [ 10 ]. Poland is a European Union country with a low HPV vaccination coverage rate (10–15% of the eligible population) [ 10 , 12 ] and a high cervical cancer burden (approximately 2500 newly diagnosed cases every year) [ 13 , 14 ].…”

Section: Introductionmentioning

confidence: 99%

National HPV Vaccination Program in Poland—Public Awareness, Sources of Knowledge, and Willingness to Vaccinate Children against HPV

et al. 2023

Self Cite

View full text Add to dashboard Cite

Since 1 June 2023, a nationwide HPV vaccination program was implemented in Poland. This study aimed to identify factors associated with public awareness of the national HPV vaccination program among adults in Poland and willingness to vaccinate children against HPV. This cross-sectional study was carried out between 14 and 17 July 2023 among 1056 adults in Poland. A self-prepared questionnaire was used. Among the respondents, 51.3% had heard about the free HPV vaccination program. The major source of knowledge on the national HPV vaccination program was TV (62%). Only 31.9% of respondents correctly indicated girls and boys aged 12 and 13 as the HPV-vaccination-eligible population. Willingness to vaccinate children against HPV was declared by 63.3% of respondents. Female gender (OR: 1.42; 95% CI: 1.11–1.81; p < 0.01), age 35–64 years (p < 0.05), having higher education (OR: 1.43; 95% CI: 1.11–1.84; p < 0.01), and living in cities with more than 500,000 residents (OR: 1.51; 95% CI: 1.01–2.28; p < 0.05) were significantly associated with higher odds to hear about the national HPV vaccination program. Age 50 years and over (p < 0.05), having higher education (OR: 1.43; 95% CI: 1.09–1.88; p < 0.05), living in cities with more than 500,000 residents (OR: 1.80; 95% CI: 1.14–2.83; p < 0.05), and no children under 18 in the home (OR: 1.39; 95% CI: 1.01–1.89; p < 0.05) were significantly associated with willingness to vaccinate children against HPV.

show abstract

“…Poland ranks eighth for incidence of CC and fifth for deaths. The five-year survival rate in Poland is 48.3% (the EU average is 62.1%) [ 2 ].…”

Section: Introductionmentioning

confidence: 99%

Cervical Cancer Prophylaxis—State-of-the-Art and Perspectives

Poniewierza¹,

Panek

2022

Healthcare

View full text Add to dashboard Cite

Background: Each year 604,127 new cases of cervical cancer (CC) are diagnosed, and 341,831 individuals die from the disease. It is the fourth most common cancer among women and the fourth most common cause of death from female cancers worldwide. The pathogenesis of CC is associated with human papillomavirus (HPV) infections and consists of several steps involving cell proliferation outside the human body’s control mechanisms. Strategies to prevent CC are based on screening and vaccination. Scope of the Review: The aim of this paper was to collect and analyze the available literature on the issue of CC prevention and the impact of the COVID-19 pandemic on its implementation. For this purpose, PubMed and Google Scholar databases were searched using keywords, such as “cervical cancer”; “HPV”; “prevention”; “prophylaxis”; “vaccination”; “screening” and “COVID-19” in different variations. Only articles published since 2018 were included in the study. Conclusions: Selected European countries have different CC prevention programs funded by national budgets. This translates into observed differences in the risk of death from CC (age-standardized rate Malta = 1.1, Poland = 5.9). COVID-19 pandemic due to disruption of CC screening may exacerbate these differences in the future. To improve the situation, new screening methods, such as p16/Ki67, HPV self-testing, and the use of artificial intelligence in colposcopic assessment, should be disseminated, as well as free HPV vaccination programs implemented in all countries. The search for new solutions is not without significance and entails ultra-sensitive screening tests for risk groups (mRNA E6/E7, SOX1/SOX14), HPV vaccines with shorter dosing schedules, and new therapeutic pathways using nanotheranostics.

show abstract

Overall survival (OS) in patients after chemotherapy for cervical cancer in Poland in years 2008–2015

Abstract: This article has been peer reviewed and published immediately upon acceptance.It is an open access article, which means that it can be downloaded, printed, and distributed freely, provided the work is properly cited. Articles in "Ginekologia Polska" are listed in PubMed.

Cited by 3 publications

References 5 publications

Cervical Cancer Prevention in the Era of the COVID-19 Pandemic

Cervical Cancer Prevention in the Era of the COVID-19 Pandemic

National HPV Vaccination Program in Poland—Public Awareness, Sources of Knowledge, and Willingness to Vaccinate Children against HPV

Cervical Cancer Prophylaxis—State-of-the-Art and Perspectives

Contact Info

Product

Resources

About